The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency - PubMed (original) (raw)
Clinical Trial
. 2009 Mar-Apr;38(2):149-53.
doi: 10.1080/03009740802419081.
Affiliations
- PMID: 18991184
- DOI: 10.1080/03009740802419081
Clinical Trial
The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency
P Leventis et al. Scand J Rheumatol. 2009 Mar-Apr.
Abstract
Objectives: To investigate the practicality and tolerability of high-dose intramuscular (i.m.) vitamin D2 or oral vitamin D3 replacement in vitamin D-insufficient patients, and to evaluate the biochemical efficacy of each formulation.
Methods: Sixty-nine patients with vitamin D insufficiency [25-hydroxyvitamin D (25(OH)D) <40 nmol/L] were recruited from the Rheumatology Outpatient Department of St George's Hospital, London. In study 1, 50 patients received 300 000 IU i.m. vitamin D2 (ergocalciferol). In study 2, 19 patients received 300 000 IU oral vitamin D3 (cholecalciferol) under observation. Biochemical response was measured at baseline, and at 12 and 24 weeks.
Results: Bolus i.m. vitamin D2 or oral vitamin D3 was well tolerated. The change from baseline in serum 25(OH)D was significantly greater at 6 and 12 weeks in study 2 (p<0.0001 and <0.0001, respectively). In study 1, a modest increase in mean serum 25(OH)D at 6, 12, and 24 weeks was observed but no patients achieved a serum 25(OH)D concentration > or = 50 nmol/L. PTH remained elevated in 42% of patients with secondary hyperparathyroidism at 12 weeks. In study 2, 100% and 89% of patients had serum 25(OH)D>50 nmol/L at 6 and 12 weeks, respectively. All patients with elevated baseline PTH were fully suppressed at 12 weeks. No cases of hypercalcaemia were observed in either group.
Conclusion: The 300 000-IU bolus of vitamin D2 or D3 was practical, well tolerated, and safe. Vitamin D3 had greater potency than equimolar vitamin D2, with a higher, sustained serum 25(OH)D response and efficacious PTH suppression. To adequately treat vitamin D insufficiency we would recommend administering 300,000 IU oral vitamin D3 approximately three times per year.
Similar articles
- Vitamin D-deficiency in the elderly: treatment with ergocalciferol and hydroxylated analogues of vitamin D3.
Shany S, Chaimovitz C, Yagev R, Bercovich M, Lowenthal MN. Shany S, et al. Isr J Med Sci. 1988 Mar;24(3):160-3. Isr J Med Sci. 1988. PMID: 3259568 - Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PA. Hiremath GS, et al. Mult Scler. 2009 Jun;15(6):735-40. doi: 10.1177/1352458509102844. Epub 2009 Apr 21. Mult Scler. 2009. PMID: 19383644 - Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation.
Jean G, Souberbielle JC, Chazot C. Jean G, et al. Nephrol Dial Transplant. 2009 Dec;24(12):3799-805. doi: 10.1093/ndt/gfp370. Epub 2009 Jul 21. Nephrol Dial Transplant. 2009. PMID: 19622574 Clinical Trial. - Correcting poor vitamin D status: do older adults need higher repletion doses of vitamin D3 than younger adults?
Whiting SJ, Calvo MS. Whiting SJ, et al. Mol Nutr Food Res. 2010 Aug;54(8):1077-84. doi: 10.1002/mnfr.200900536. Mol Nutr Food Res. 2010. PMID: 20440693 Review.
Cited by
- Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.
Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC, Bollerslev J, Bouillon R, Brandi ML, Casanueva FF, di Filippo L, Donini LM, Ebeling PR, Fuleihan GE, Fassio A, Frara S, Jones G, Marcocci C, Martineau AR, Minisola S, Napoli N, Procopio M, Rizzoli R, Schafer AL, Sempos CT, Ulivieri FM, Virtanen JK. Giustina A, et al. Endocr Rev. 2024 Sep 12;45(5):625-654. doi: 10.1210/endrev/bnae009. Endocr Rev. 2024. PMID: 38676447 Free PMC article. - Vitamin D and eye: Current evidence and practice guidelines.
Gorimanipalli B, Shetty R, Sethu S, Khamar P. Gorimanipalli B, et al. Indian J Ophthalmol. 2023 Apr;71(4):1127-1134. doi: 10.4103/IJO.IJO_3174_22. Indian J Ophthalmol. 2023. PMID: 37026244 Free PMC article. Review. - Efficacy and Safety of a Personalized Vitamin D3 Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial.
Kuznia S, Czock D, Kopp-Schneider A, Caspari R, Fischer H, Laetsch DC, Slavic M, Brenner H, Schöttker B. Kuznia S, et al. Nutrients. 2022 Oct 28;14(21):4546. doi: 10.3390/nu14214546. Nutrients. 2022. PMID: 36364809 Free PMC article. Clinical Trial. - Effectiveness of vitamin D2 compared with vitamin D3 replacement therapy in a primary healthcare setting: a retrospective cohort study.
Alayed Albarri EM, Sameer Alnuaimi A, Abdelghani D. Alayed Albarri EM, et al. Qatar Med J. 2022 Aug 4;2022(3):29. doi: 10.5339/qmj.2022.35. eCollection 2022. Qatar Med J. 2022. PMID: 35974883 Free PMC article. - Effects of Monthly Intramuscular High-Dose Vitamin D2 on Serum 25-Hydroxyvitamin D and Immune Parameters in Very Elderly Chinese Patients with Vitamin D Deficiency.
Bian P, Jin X, Shou Z. Bian P, et al. Int J Endocrinol. 2021 Oct 18;2021:1343913. doi: 10.1155/2021/1343913. eCollection 2021. Int J Endocrinol. 2021. PMID: 34707657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical